Professor

Phone: (027)87792148

Email: luqw@hust.edu.cn

Academic Areas: Cardiovascular Pathophysiology

Research Interests: Molecular pathogenic mechanism of cardiomyopathy; Biological application of nanomaterial

Academic Degrees

PhD(2000-2015) in Department of Clinical Pharmacology, Graduate School of Medical Sciences, Kyushu University, Japan

BS(1989-1993) in Department of Biology, Hubei University, China

Professional Experience

Professor(2010-present): College of Life Science and Technology, Huazhong University of Science and Technology, China

Research Associate(2007-2010): Department of Physiology and Biophysics and Center for Cardiovascular Research, College of Medicine, University of Illinois at Chicago, USA

Postdoctoral Research Fellow(2005-2007): Department of Clinical Pharmacology, Graduate School of Medical Sciences, Kyushu University; JSPS(Japan Society for the Promotion of Science), Japan

Research Assistant(1993-1998): WuHan Biological Products Institute of Chinese Health Ministry, China

Selected Publications

1. Luo W, Xu R, Liu YF, et.al. Emulsion-templated poly(acrylamide)s by using polyvinyl alcohol (PVA) stabilized CO2-in-water emulsions and their applications in tissue engineering scaffolds. RSC Adv. 5(112): 92017-92024, 2015

2. Luo W, Zhang SC, Li P, et.al. Surfactant-free CO2-in-water emulsion-templated poly (vinyl alcohol) (PVA) hydrogels. Polymer 61: 183-191, 2015

3. Dong QH, Chen L, Lu QW, et.al. Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression. Br J Pharmacol. 171(19):4440-4454, 2014

4. Li L, Guo QL, Li J, et.al. Design of a polymer ligand for one-step preparation of highly stable fluorescent Ag5 clusters for tissue labeling. J of Mater Chem B. 1 (32):3999-4004, 2013

5. Majeed I, Lu QW, Yan W, et.al. Highly Water-Soluble Magnetic Iron Oxide (Fe3O4) Nanoparticles for Drug Delivery Enhanced In Vitro Therapeutic Efficacy of Doxorubicin and MION Conjugates. J of Mater Chem B. 1(22):2874-2884, 2013

6. Lu QW, Wu XY, Morimoto S. Inherited cardiomyopathies caused by troponin mutations (review). J Geriatr Cardiol. 10(1):91-101,2013

7. Wang F, Simen A, Arias A, et.al. A large-scale meta-analysis of the association between the ANKK1/DRD2 Taq1A polymorphism and alcohol dependence. Hum Genet. 132(3):347-58, 2013

8. Lu QW, Morimoto S, Li L, et.al. HCM-linked troponin I mutation D127Y increases the cardiac myofilament Ca2+ sensitivity in a manner dependent on Ser23/24 phosphorylation. J Pharmacol Sci. 118: 244, 2012

9. Liu Y, Lu QW, Chen LM. Physiology and pathophysiology of Na/HCO-cotransporter NBCe1. Acta Physiologica Sinica. 64(6):729-40, 2012

10. Tadano N, Du CK, Yumoto F, et.al. Biological actions of green tea catechins on cardiac troponin C. Br J Pharmacol. 161(5):1034-43, 2010

11. Wang YY, Morimoto S, Du CK, et.al. Up-regulation of type 2 iodothyronine deiodinase in dilated cardiomyopathy.  Cardiovasc Res. 87(4):636-46, 2010

12. Lu QW, Hinken AC, Patrick SE, et.al. Phosphorylation of cardiac troponin I at protein kinase C site threonine-144 depresses the cooperativity in thin filament. J Biol Chem. 285(16):11810-7, 2010

13. Zhan DY, Morimoto S, Du CK, et.al. Therapeutic effect of beta-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation. Cardiovasc Res. 84(1): 64-71, 2009

14. Nishii K, Morimoto S, Minakami R, et.al. Targeted disruption of the cardiac troponin T gene causes sarcomere disassembly and defects in heartbeat within the early mouse embryo. Dev Biol. 322(1):65–73, 2008

15. Du CK, Morimoto S, Nishii K, et.al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res. 101(2):185-94, 2007

16. Yumoto F, Lu QW, Morimoto S, et.al. Drastic Ca2+ sensitization of myofilament associated with a small structural change in troponin I in inherited restrictive cardiomyopathy. Biochem Biophys Res Commun. 23;338(3):1519-26, 2005

17. Lu QW, Morimoto S, Harada K, et.al. Cardiac troponin T mutation R141W found in dilated cardiomyopathy stabilizes the troponin T - tropomyosin interaction and causes a Ca2+-desensitization. J Mol Cell Cardiol. 35(12):1421-1427, 2003

18. Morimoto S, Lu QW, Harada K, et.al. Ca2+-desensitizing effect of a deletion mutation ∆K210 in cardiac troponin T that causes familial dilated cardiomyopathy. PNAS. 22;99(2):913-8, 2002

19. Takahashi-Yanaga F, Morimoto S, Harada K, et.al. Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 33(12):2095-107, 2001

Courses Taught

0700893: Cell Biology

170.541: Molecular Developmental Biology

Project

1. Molecular mechanisms of muscle wound healing. Hubei Provincial Collaborative Innovation(2014-2016)

2. A novel mechanism of cardiac function regulated by cTnI through PKCβ and MMP2. Fundamental Research Funds for the Central Universities(2015-2016)

3. Molecular mechanism of cTnC in hypertrophic cardiomyopathy. SRF for ROCS, SEM(2013-2014)

4. The consequences of troponin mutations in heart development. Fundamental Research Funds for the Central Universities(2013-2014)

5. Pak1 in therapy for cardiac hypertrophy. Fundamental Research Funds for the Central Universities(2011-2012)

6. Molecular pathogenic mechanism of inherited cardiomyopathies caused by mutations in cardiac troponin. JSPS(2005-2007)

7.  Actin filaments, from structure to mechanism. MEXT(2001-2007)


 

Login and edit information